Pinned straw:
On the positive side, Vysarn maintained good cash reserves, minimal debt and disciplined capital management. Segment contributions are better balanced, reducing reliance on the drilling business. Management aims to carry its H2 FY 2025 run rate into FY 2026 and continue national expansion, particularly in technology and consulting.
Key risks include ongoing CMP integration challenges, execution across a broader geographic footprint and cyclicality in the Industrial division.
Although I don’t have analyst estimates available for 2 yr EBITDA CAGR I presume Vysarn will do roughly 30% EBITDA next year (or slightly higher if they are conservative in their guidance of 31% NPBT growth for FY26) and hopefully 20% for FY27.Based on these assumptions dividing NTM EV/EBITDA on FWD 2 Year EBITDA CAGR gives me roughly 0.42. ((282/27)/25) from my back of the envelope calculation.
I’ve been subscribing to Jonah Lupton’s service for US stocks. He’s looking for this number to be below 0.5 with the aim of finding shares that are able to double in price over the next 2-3 years through a mix of unappreciated growth and valuation expansion. (I believe he’s using EBITA in his calculations but EBITDA may be better for an asset heavy company like Vysarn).
If we turn around the negatives – the trouble they had with integrating CMP and a continued turn around for the Industrial Segment with more tier 1 clients, higher utilisation and expansion of reinjection testing services there could be an upside to this estimate as well I.e. a ratio below 0.4.and further appreciation of the share price as more brokers and the market pays attention.
Market must have been expecting more which i think is rather harsh. Quietly executing nicely and has agood long term growth potential
disc- held in RL and SM